Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations
复制标题
DOI：
10.1016/j.jaci.2018.07.020
复制
发表时间：
2018-11-01
影响因子：
14.2
通讯作者：
Leiding, Jennifer W.
中科院分区：
文献类型：
--
作者：
Forbes, Lisa R.;Vogel, Tiphanie P.;Leiding, Jennifer W.
摘要：STAT1 GOF或STAT3 GOF疾病患者的自身免疫和免疫失调特征的治疗仍然具有挑战性。Jakinibs已用于治疗STAT1 GOF或STAT3 GOF突变患者的严重免疫失调。
Brief Summary: Treatment of the autoimmune and immune-dysregulatory features of patients with STAT1 GOF or STAT3 GOF disease remains challenging. Jakinibs have been used to treat the severe immune-dysregulation in patients with either STAT1 GOF or STAT3 GOF mutations.